Record overview
Status and phase
Status: ACTIVE_NOT_RECRUITING
Phase: PHASE2
Sponsor: AstraZeneca
Condition: Non-Small Cell Lung Cancer
NCT03944772
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Low Signal
Timeline signals: stale_update_signal | primary_completion_date_past_signal | completion_date_past_signal | long_recruitment_duration_signal
Results signal: Low Signal
Operational burden: large_enrollment_target_signal | rare_population_signal | strict_eligibility_signal
Stopped reason
Context when available
No stop reason available in the current public record.